Explore the latest news from Khondrion and its team.
Khondrion announces completion of patient recruitment and first-in-patient dosing in its KHENERGY study, a phase 2 clinical...
THE KHENERGYC STUDY: European Union EFRO grant to boost the development of Khondrion’s KH176 for children with mitochondrial...
Khondrion initiates the KHENERGY study, a phase 2 clinical trial of KH176 in MELAS/MIDD and mixed mitochondrial syndromes...
Press Release New EU research project REMIX joins forces between universities’ research facilities and Khondrion New EU...
December 4, 2015 - FOR IMMEDIATE RELEASE Khondrion reports successful outcome of KH176 Phase 1 Clinical trials NIJMEGEN – Khondrion, the...
Khondrion has received an Orphan Drug Designation from the European Commission of its frontrunner compound...
1. Tell us about your career before joining Khondrion.I qualified as a Medical Doctor from the University of Utrecht and worked clinically in the...
Cognition is an important function of the brain so we can gain knowledge and understanding. These mental processes include thinking, knowing,...
Classic MELAS syndrome (Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes), MIDD (maternally inherited diabetes mellitus...
1. Tell us all about your career before joining Khondrion I studied pharmacology and molecular biology at the University of Strasbourg in France,...
Chief Executive Officer of Khondrion, Prof. Dr. Jan Smeitink, reflects on the Mitochondrial Medicine conference held from 11-13 December 2019 at the...
Members of the Khondrion team will be attending Mitochondrial Medicine 2019 on 11-13 December 2019. The event will bring together...
